Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

LATEST NEWS

First Lady of Ghana Encourages Healthy Ghanaians to Become Champions of Change and Donate Blood to Save Lives

Terumo BCT Evolves Brand to Terumo Blood and Cell Technologies

Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults

A Look Inside Terumo BCT's Impact on Convalescent Plasma for COVID-19

First COVID-19 Patient Receives Therapy Targeting Cytokine Storm Under FDA EUA

Terumo BCT’s Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Terumo BCT’s Mirasol Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets

Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients

Terumo BCT Message: COVID-19

Terumo BCT’s Mirasol® Pathogen Reduction Technology (PRT) System Demonstrates Reduced Risk of Transfusion Transmission of MERS-CoV, a strain of Coronavirus

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}